Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer.

@article{Manegold2008AntiangiogenicTW,
  title={Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer.},
  author={Philipp C. Manegold and Carmen Paringer and Ulrike Kulka and Klaus Krimmel and Martin E. Eichhorn and Ralf Wilkowski and K H Jauch and Markus Guba and Christiane J Bruns},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2008},
  volume={14 3},
  pages={892-900}
}
PURPOSE Radiotherapy exerts direct antivascular effects in tumors and also induces a proangiogenic stress response in tumor cells via the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway. Therefore, the combination of radiotherapy and antiangiogenic therapy with mTOR inhibitor RAD001 (Everolimus) might exert additive/synergistic effects on tumor growth. EXPERIMENTAL DESIGN Effects of radiation combined with mTOR inhibitor RAD001 were studied on proliferation of… CONTINUE READING